Skip to main content

The Kefallinia Score: Development and Apparent Performance Assessment of a Flow Cytometry-Based Intraoperative Classification System for Intracranial Tumors

In brief

A flow cytometry score matched pathology in 90% of 90 brain tumors

In a retrospective analysis, the Kefallinia Score assigned 81 of 90 intracranial tumors to the category matching their final pathology, for 90% apparent accuracy. It uses DNA content and selected immune and tumor markers to sort tumors into four broad groups; only two cases were lymphoma, and prospective testing is needed before clinical use.

Journal
Cancers (Q1)
Published
4 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Georgios S Markopoulos, Alexandros Liaropoulos, Evrysthenis Vartholomatos, Konstantinos Liaropoulos, Spyridon Voulgaris, George Alexiou, et al.
PMID
43026868
DOI
10.3390/cancers18213547

Why clinicians should know about it

Abstract

BACKGROUND: Intraoperative flow cytometry (iFC) provides rapid quantitative information on DNA content, cell-cycle distribution, tumor index, ploidy, and selected immunophenotypic features during tumor surgery. Existing iFC studies in neurosurgery have mainly focused on glioma grading, meningioma grade assessment, margin evaluation, or specific binary diagnostic questions. In this study, we evaluated the Kefallinia Score as an iFC-based classification system for broad diagnostic orientation in neurosurgery. METHODS: We retrospectively analyzed a de-identified, complete-panel dataset from 90 patients with intracranial tumors. The score combined DNA-index abnormality, tumor index, an operational low-DNA-content fraction, CD20/CD45/CD19 positivity, cytokeratin positivity, and glial fibrillary acidic protein (GFAP) expression. Score intervals assigned cases to low-grade/meningioma-predominant (0-4), glioma-spectrum (5-14), lymphoma-oriented (15-29), or metastasis-oriented (≥30) categories. The scoring rules were defined before specimen collection and evaluated retrospectively against final routine pathological diagnoses. RESULTS: The cohort included 41 low-grade/meningioma-predominant lesions, 36 glioma-spectrum tumors, two lymphomas, and 11 metastases. Apparent accuracy was 90.0% (81/90; 95% CI, 81.9-95.3%) and balanced accuracy was 92.85% (95% stratified bootstrap CI, 87.1-97.6%). Sensitivity/specificity were 80.5%/98.0%, 100.0%/87.0%, 100.0%/98.9%, and 90.9%/100.0%, respectively. CONCLUSIONS: These findings support further evaluation of the classification framework to assess possible future clinical use.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.